Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Severe Worsening of Trigeminal Neuralgia Associated with Dalfampridine Treatment in Patients with Multiple Sclerosis
MS and Related Diseases
S30 - (-)
004
Dalfampridine (4-aminopyridine), a broad spectrum, voltage dependent potassium channel blocker, improves action potential conduction in demyelinated axons and has modest success in improving ambulation in a subset of patients with multiple sclerosis (MS). However, by improving conduction in injured sensory nerves, the potential for inducing or worsening sensory symptoms, such as trigeminal neuralgia, is possible.
We reviewed records of persons in our clinic with MS who were placed on dalfampridine since the availability of this drug in 2010. Details of their histories and responses to withdrawal of dalfampridine are described below.
In this retrospective analysis four patients, three women and one man, noted either a de-novo appearance of, or a major exacerbation of, severe facial pain characteristic of trigeminal neuralgia within weeks of starting dalfampridine. Facial pain was new in the male, though he had previous facial numbness on the side of the pain. Pre-existing facial pain in the three women, previously well controlled on low doses of carbamazepine, dramatically worsened. Brain MRIs obtained in all patients at onset of their worsened pain were stable. Stopping dalfampridine was associated with improved facial pain in two patients within several weeks of drug cessation. In the remaining two patients the worsened facial pain has persisted for more than a year, in one case refractory to even high doses of carbamazepine, a pattern different than previously noted.
Administration of the potassium channel blocking drug dalfampridine, while improving motor function in a subset of persons with MS, was associated with the appearance or worsening of severe trigeminal neuralgic pain, in one insistence refractory for over a year after drug withdrawal. Dalfampridine should be used with caution in patients with substantive sensory nerve dysfunction.
Authors/Disclosures
Gary Birnbaum, MD, FÂ鶹´«Ã½Ó³»­
PRESENTER 		No disclosure on file
Walter Poellmann, MD (Marianna-Strauss-Klinik) No disclosure on file
No disclosure on file